Health Economics From a Regulatory Perspective

Health Economics From a Regulatory Perspective
Health economics and Health Technology Assessment (HTA) during the development of a new drug are becoming increasingly important. If a drug is to reach the patient after regulatory approval, it must undergo a health economic evaluation, a basis for pricing and decisions on subsidies. This takes place at national level in the various EU countries. Hear from TLV and Industry about the new EU HTA Regulation (EU) 2021/2282 (HTAR) which will be applied from January 2025 for certain medicines, Joint Clinical Assessment (JCA) and HTA strategy during drug development. This evening is an excellent opportunity to hear the latest in this field. You also get the opportunity to meet colleagues in a relaxed and sociable setting.

Date: Tuesday 22 October 2024
Time: 17:00-20:00 GMT / 18:00 – 21:00 CET

Please note this is a face to face presentation, conducted in Swedish.
Address: Medical Products Agency, Dag Hammarskjölds väg 42, Uppsala

Programme


18:00 - 18:30           The evening begins with light refreshments

18:30 - 18:35           Introduction
                                     Margareth Jovid, TOPRA Volunteer

18:35 - 18:50           From regulatory approval to the patient
                                     Anna Mäkinen Salmi, Medical Products Agency, Uppsala

18:50 - 19:15           HTA and strategy during drug development               
                                            -  What is HTA and PICO
                                            -  HTA Strategy
                                    Åsa By, Macanda and SHEA


19:15 - 19:40           EU HTA Regulation - (EU) 2021/2282 (HTAR)
                                            -  Content and timelines
                                            -  How is the work at TVL affected
                                            -  Joint Clinical Assessments (JCA)
                                     Maria Eriksson, TLV, Stockholm


19:40 - 19:55           Short Break

20:20 - 21:00           The industry's perspective on EU HTA
                                           -  What opportunities and challenges does the industry see
                                           -  How the industry is preparing
                                           -  Tips to consider
                                    Emma Sabelström, Abbvie/LIF

20:20 - 21:00           Time for questions

Pricing

TOPRA Members: Free [MPA employees - Free. Use code MPA200]
Non-member: £45 (includes 2 months TOPRA membership)

Contact us

Contact membership@topra.org or Margareth Jorvid at margareth.jorvid@lsmgroup.se if you want to become TOPRA member.

Questions: toprainsweden@topra.org

How to register

Members: Use the 'Register now' form above to log in to the site with your TOPRA Member username and password. Once logged in click the 'Register Myself' button that will appear below.

Non-members: If you already have non-member account for this site, log in and then click the 'Register Myself' link that will appear below.

If you do not have an account, create an account, then log in and click the 'Register Myself' link that will appear below.

Any questions, contact: toprainsweden@topra.org.
When
22/10/2024
Where
MPA, Dag Hammarskjölds Väg 42 UPPSALA SWEDEN
Sign in or create an account to register Registration ends 22/10/2024 15:00 (GMT Daylight Time)
My registration status: Not registered
Your company name
Your VAT country
Your VAT number
NOTE
Important instructions before booking - If your company name or VAT number does not appear here or you would like to be invoiced using a different VAT number, please email finance@topra.org

Register now